INBX
Price
$28.18
Change
+$0.46 (+1.66%)
Updated
Sep 5 closing price
Capitalization
408.2M
67 days until earnings call
ZYME
Price
$15.05
Change
+$0.97 (+6.89%)
Updated
Sep 5 closing price
Capitalization
1.14B
Interact to see
Advertisement

INBX vs ZYME

Header iconINBX vs ZYME Comparison
Open Charts INBX vs ZYMEBanner chart's image
Inhibrx Biosciences
Price$28.18
Change+$0.46 (+1.66%)
Volume$151.23K
Capitalization408.2M
Zymeworks
Price$15.05
Change+$0.97 (+6.89%)
Volume$627.5K
Capitalization1.14B
INBX vs ZYME Comparison Chart in %
Loading...
INBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INBX vs. ZYME commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INBX is a Buy and ZYME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (INBX: $28.18 vs. ZYME: $15.05)
Brand notoriety: INBX and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INBX: 126% vs. ZYME: 141%
Market capitalization -- INBX: $408.2M vs. ZYME: $1.14B
INBX [@Biotechnology] is valued at $408.2M. ZYME’s [@Biotechnology] market capitalization is $1.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INBX’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • INBX’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than INBX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INBX’s TA Score shows that 4 TA indicator(s) are bullish while ZYME’s TA Score has 6 bullish TA indicator(s).

  • INBX’s TA Score: 4 bullish, 3 bearish.
  • ZYME’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, both INBX and ZYME are a good buy in the short-term.

Price Growth

INBX (@Biotechnology) experienced а -0.07% price change this week, while ZYME (@Biotechnology) price change was +1.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

INBX is expected to report earnings on Nov 13, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZYME($1.14B) has a higher market cap than INBX($408M). INBX YTD gains are higher at: 82.987 vs. ZYME (2.801). ZYME has higher annual earnings (EBITDA): -69.77M vs. INBX (-155.08M). ZYME has more cash in the bank: 281M vs. INBX (187M). ZYME has less debt than INBX: ZYME (18.7M) vs INBX (107M). ZYME has higher revenues than INBX: ZYME (123M) vs INBX (1.4M).
INBXZYMEINBX / ZYME
Capitalization408M1.14B36%
EBITDA-155.08M-69.77M222%
Gain YTD82.9872.8012,963%
P/E Ratio0.20N/A-
Revenue1.4M123M1%
Total Cash187M281M67%
Total Debt107M18.7M572%
FUNDAMENTALS RATINGS
ZYME: Fundamental Ratings
ZYME
OUTLOOK RATING
1..100
83
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
63
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
INBXZYME
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
78%
MACD
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 12 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
INBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VGLSX11.050.03
+0.27%
VALIC Company I Global Strategy
PEIQX42.890.04
+0.09%
Principal Equity Income R5
JGECX12.99N/A
N/A
JHancock Global Equity C
USGLX65.34-0.34
-0.52%
JHancock U.S. Global Leaders Growth A
MEIFX14.01-0.08
-0.57%
Meridian Hedged Equity Legacy

INBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, INBX has been loosely correlated with COGT. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if INBX jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INBX
1D Price
Change %
INBX100%
+1.66%
COGT - INBX
42%
Loosely correlated
+0.85%
ACET - INBX
39%
Loosely correlated
+1.00%
STOK - INBX
37%
Loosely correlated
+5.35%
ZYME - INBX
36%
Loosely correlated
+6.89%
IPSC - INBX
36%
Loosely correlated
+5.41%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with NRIX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
+6.89%
NRIX - ZYME
51%
Loosely correlated
+8.66%
ABEO - ZYME
48%
Loosely correlated
+0.44%
CRNX - ZYME
47%
Loosely correlated
+3.97%
ELVN - ZYME
47%
Loosely correlated
+0.70%
BEAM - ZYME
47%
Loosely correlated
+12.62%
More